Indobufen(CAS NO.:63610-08-2)

Indolebufen is an antiplatelet aggregation drug, which can selectively act on circulating platelets, block thrombosis, inhibit the release of platelet factors and exert antiplatelet aggregation effect, this inhibition is reversible, does not change plasma parameters, does not affect platelet function, and normalizes abnormal platelet function. It can significantly improve the microcirculatory parameters and walking distance in patients with peripheral vascular lesions and intermittent claudication, and prevent obstruction after coronary artery shunt and femoral shunt, which is comparable to that of aspirin plus dipyridine; During hemodialysis, it can significantly reduce platelet deposits on the dialysis membrane, and this product can also prevent secondary thrombosis after a transient ischemic attack or mild stroke. Compared with similar drugs, indolebufen inhibits platelet factors, and the anti-platelet aggregation effect is 2~5 times that of salicylic acid, and it has a shorter bleeding time than a slight duration. There was no significant difference in oral efficacy compared with ticlopidine, but indobufen was well tolerated.